Bellerophon Eyes $69M IPO After Spinoff From Ikaria
Private equity-backed biotech Bellerophon Therapeutics LLC, which is developing therapies and medical devices for cardiopulmonary diseases, filed on Tuesday for an up to $69 million initial public offering as it ramps...To view the full article, register now.
Already a subscriber? Click here to view full article